Yabao Pharmaceutical Group Co Ltd

Yabao Pharmaceutical announced on September 11 that the company repurchased 200,000 shares for the first time, accounting for 0.03% of total share capital, with a repurchase amount of 1.32 million yuan and a repurchase price range of 6.58 yuan to 6.59 yuan per share. In the first half of 2026, Yabao Pharmaceutical achieved revenue of 1.145 billion yuan and net profit attributable to the parent company of 178 million yuan.

Yabao Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company reaching 178 million yuan, up 1.83% from the same period last year. During the reporting period, total operating revenue was 1.145 billion yuan, a slight year-on-year increase of 0.49%. Net cash inflow from operating activities was 353 million yuan, up 7.81% year-on-year. The company's latest asset-liability ratio stands at 15.03%, down 3.82 percentage points from the same period last year. Gross margin was 53.99%, rising for three consecutive quarters and up 1.43 percentage points year-on-year. Diluted earnings per share were 0.26 yuan, achieving five consecutive years of growth, with a year-on-year increase of 3.34%.

Yabao Pharmaceutical announced that its wholly-owned subsidiary, Yabao Pharmaceutical Sichuan Pharmaceutical, received a drug registration certificate for levocetirizine hydrochloride oral solution from the National Medical Products Administration on July 31, 2026. The specifications include 75 milliliters to 37.5 milligrams and 150 milliliters to 75 milligrams, classified as a chemical drug category 3. The company's cumulative research and development investment reached 5.006 million yuan. The company stated that this approval will help improve its product portfolio and enhance market competitiveness, and it will actively promote production and market launch going forward. However, uncertainties remain in research and development as well as sales, and investors are advised to be aware of the risks.

Yabao Pharmaceutical announced plans to repurchase shares through centralized bidding, with a buyback amount of no less than 100 million yuan and no more than 200 million yuan, at a price not exceeding 6.95 yuan per share. All repurchased shares will be cancelled to reduce the company's registered capital.